Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,750.80
(
-0.19%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.83
(
3.05%
)
Bitcoin
70,358.96
(
-1.24%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 160866

Wednesday, 05/08/2013 12:59:26 PM

Wednesday, May 08, 2013 12:59:26 PM

Post# of 257257
PTLA reports top-line phase-2 data for PRT4445 as Eliquis antidote:

http://finance.yahoo.com/news/portola-announces-factor-xa-inhibitor-120000977.html

Analysis of anticoagulation markers and plasma concentration levels of Eliquis in blood samples taken from the subjects indicates that PRT4445 produces a rapid, sustained and dose-related reversal of the anticoagulant activity of Eliquis. In addition, no serious adverse events were reported. Additional details will be presented at an upcoming medical conference.

These data are well-timed vis-à-vis PTLA’s plans to IPO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today